Clinical trials: Recurrent Head and Neck Carcinoma
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST…
- Trial name
- NCT03848286
- Testing
- KL-A167 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01175980
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and occurs in the oral cavity, pharynx and larynx.
- Trial name
- ERBIOTAX (NCT06856213)
- Testing
- Cetuximab, Paclitaxel
- Where
- 17 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01612546
- Testing
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Esophageal Squamous Cell Carcinoma
Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
This phase Ⅱ study was designed to evaluate the efficacy and safety of endostar combined with paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or metastatic esophageal squamous cell cancer.
- Trial name
- NCT02350517
- Testing
- Paclitaxel+Nedaplatin+Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Yuhong Li
Head and Neck Neoplasms
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.
- Trial name
- NCT03020823
- Testing
- SCB01A
- Where
- 4 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx
Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer
This pilot clinical trial studies photodynamic therapy using temoporfin before surgery in treating patients with recurrent oral cavity or oropharyngeal cancer.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01718223
- Testing
- photodynamic therapy, therapeutic conventional surgery, laboratory biomarker analysis
- Sponsor
- Roswell Park Cancer Institute
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system…
- Conditions
- Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
- Trial name
- NCT03074513
- Testing
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of the Head and Neck
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
This study involves another course of radiation (called re-irradiation) to the participant's tumor. The type of radiation is called stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02158234
- Testing
- Cisplatin, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Nasopharyngeal Carcinoma
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy
- Trial name
- NCT03213587
- Testing
- Apatinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients.
- Trial name
- HENEPET (NCT04196985)
- Testing
- PET/MRI, PET/CT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
This phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has…
- Trial name
- NCT05799144
- Testing
- DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Michael K. Gibson
Head and Neck Cancer
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898638
- Testing
- biologic sample preservation procedure, medical chart review
- Where
- 4 sites in United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Head and Neck Cancer
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- CARIO (NCT00963326)
- Testing
- laboratory biomarker analysis
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.